Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
Guidelines aim to establish state-regulated veterinary blood banks
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare
Subscribe To Our Newsletter & Stay Updated